Introduction
T he prostate-specific membrane antigen (PSMA) is overexpressed on the cell surface of prostate cancer (PC) cells [1] . Recent studies with gallium-68 (Ga-68)-labeled Glu-NH-CO-NH-Lys-(Ahx) ([ 68 Ga]Ga-PSMA-HBED-CC) have shown the potential of this radioligand to detect relapses and metastases of PC with improved contrast when compared to [ 18 F]fluoromethylcholine positron emission tomography (PET)/X-ray computed tomography (CT) [2] [3] [4] [5] . Additionally, iodine-124, iodine-131, and lutetium-177-labeled PSMA ligands have been reported for dosimetric and therapeutic use [6, 7] . Several PSMA inhibitors were developed which compromise different pharmacophoric structures to interact with the binding pocket for N-acetyl-L-aspartyl-L-glutamate. PSMA-binding ligands are bound to the extracellular domain of PSMA. However, the transmembranous location of the binding domain and its enzyme activity enable the subsequent internalization of these ligands. The prostate-specific membrane antigen is also expressed in the tumor-associated neovasculature of gastric and colorectal cancer [8, 9] . Thus, these PSMAselective ligands may be of interest for imaging other tumor types in the future.
In comparison to currently broadly applied Ga-68-labeled PSMA ligands, fluorine-18 (F-18)-labeled compounds would offer some important advantages. This includes not only an increase of the number of examinations owing to the higher production capacity but also an excellent image quality. The latter will be a result of optimized tracer doses leading to high imaging statistics and the decay properties of F-18 itself. F-18 exhibits a low positron emission energy of 0.6 MeV. Therefore, the distance to decelerate the positron in human tissue is much shorter in comparison to (β + -energy=2.3 MeV) resulting in a much higher image resolution. Recently, Chen and colleagues [10] have published first data on [ 18 F]DCFPyL (2-(3-{1-carboxy-5-[ (6-[ 18 F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a new PSMA-selective ligand with a high binding affinity for PSMA. It was suggested that this compound may represent a highly promising candidate for PET imaging of PSMA-overexpressing tissues [10] .
In 
Materials and Methods

Patient Characteristics
In this study, 14 selected patients were included who underwent both [ 68 Ga]Ga-PSMA-HBED-CC PET/CT and [
18 F]DCFPyL PET/ CT with the aim to determine if one of the two tracers exhibits better detection of recurrent prostate cancer and/or metastases. The patients had biochemical relapse of prostate cancer after initial curative treatment, either radical prostatectomy or radiation-based therapy. All patients showed rising PSA level and suspected progressive disease following prior treatment of prostate cancer. In 11 patients, the PSA level had increased to more than 1 ng/ml. All patients underwent the examination as part of their clinical workup. Patients were selected for the dual-scan procedure assuming that a thorough diagnostic assessment would have a significant influence on their individual subsequent therapeutic measures, i.e., local versus systemic therapy, indication for or exclusion from surgical treatment or external beam radiation therapy. This included, e.g., suspected false-negative or equivocal PET/CT results, detection of a solitary metastasis, or oligometastatic status potentially accessible for local therapy.
First, [ 68 Ga]Ga-PSMA-HBED-CC PET/CT was performed, representing the standard procedure at our center. Subsequently, in 14 selected patients, additional [ 18 F]DCFPyL PET/CT was carried out within a period of 3 weeks following the first scan. All patients underwent the examinations as part of the clinical workup in order to accumulate diagnostic evidence and potentially optimize their individual treatment. This study does not represent a systematic clinical trial, comparing the clinical value of two diagnostic instruments in a blinded fashion. All patients signed informed consent regarding the scientific evaluation of their data.
Preparation of [ 68 
Ga]Ga-PSMA-HBED-CC
[ 68 Ga]Ga-PSMA-HBED-CC was produced according to the methods reported by Eder et al. [11] and Schäfer et al. [12] . The whole labeling procedure was carried out under good manufacturing practice (GMP) conditions. For labeling, a 68 Ge/ 68 Ga-generator (iThemba), distributed by IDB Holland BV (Baarle-Nassau, the Netherlands), was used. After fractionated elution with 5 ml 0.6 M HCl, 500 μl Ga-68 generator eluate were neutralized with 250 μl 2 M sodium acetate solution (in Ultrapur water, sterilized in 1 ml aliquots). Then, 500 μl (5 μg in water, Ultrapur, Merck, Darmstadt, Germany) of PSMA-HBED-CC (ABX, Radeberg, Germany; CA index name: 4,6,12,19- The PSMA enzyme inhibition potency of compound 3 was determined with a modified Amplex Red glutamic acid assay after incubation with the cell lysates of LNCaP cell extracts in the presence of NAAG for 2 h at 37°C. The enzyme inhibitory constant (Ki) for compound 3 was 1.1±0.1 nmol/l, comparable with that of ZJ-43, which was 1.4±0.2 nmol/l under same measurement conditions. ZJ-43 is a urea-based potent inhibitor of NAAG and is used as an internal reference in the assay.
Imaging
The mean dosage of 128. [14] . Attenuation correction was performed using the low-dose non-enhanced CT data.
To ensure comparability between different PET/CT scanners, reconstruction was performed via an OSEM algorithm (4 iterations and 14 subsets), followed by an intrinsic 5-mm Gaussian filter in all directions for the Biograph 16 True Point (Siemens Medical Solutions), containing full-ring dedicated PET and 16-slice CT instrumentation. When using the Biograph mCT Flow-Edge 128 PET/CT system (Siemens Medical Solutions) with a 128-slice spiral CT, iterative reconstruction was performed using 4 iterations and 12 subsets by an intrinsic 5-mm Gaussian filter.
Image Analysis
Image analysis was performed using an appropriate workstation and software (Syngo TrueD, Siemens, Erlangen, Germany). Clinical PET/CT reading was performed by three experienced specialists from the department of nuclear medicine and from the department of radiology in consensus in a side-by-side analysis of the results obtained with both tracers. Lesions were visually interpreted as suspicious for local relapse, lymph node metastasis, bone metastasis, or visceral metastasis.
The standardized uptake value (SUV) max was measured in up to three hottest lesions (as identified in the [ 
Results
Patient characteristics are shown in Table 1 . The additional suspicious lesions detected with [ 18 F]DCFPyL were found in the lumbar vertebra L2 in a patients with bone metastases in the left humerus and the right femur (patient 2), in a pelvic lymph node beyond the vena cava inferior in a patient with a concordant left iliac PSMA-positive lymph node metastasis (patient 7), and in mediastinal, left cervical, left supraclavicular, left axillary lymph nodes as well as in the thoracal vertebra Th3 and the 
Presence of PSMA-Positive Lesions
Verification of Lesions
The bone metastases in the lumbar vertebra L2 (patient 2) and in the thoracal vertebral Th3 (patient 12) were confirmed by CT retrospectively. In patient 7, a concordant left iliac PSMA-positive lymph node was detected with both tracers and an additional F-18 PSMApositive pelvic lymph was reported. This patient underwent surgical lymph node resection, and the left iliac metastasis was confirmed histologically. The additional pelvic metastasis was not detected by salvage lymph node dissection, but PSA remained increased postoperatively, indicating that this lesion may have represented the remaining PSA-producing tissue. In 1 patient, the solitary PSMA spot in the irradiated prostate, seen in the [ 6 8 Ga]Ga-PSMA-HBED-CC PET/CT and in the [ 18 F]DCFPyL PET/CT, was not confirmed by core biopsy (patient 4). In 1 patient, the concordant solitary PSMA-avid lymph node metastasis was confirmed histologically by systematic lymphadenectomy, while core biopsy was negative for local relapse despite a focal PSMA concentration within the irradiated prostate (patient 1). Examples of the PSMA-positive lesions are shown in Figs. 1, 2, 3 , and 4.
Quantitative Comparison
The mean SUV max in the concordant PSMA-positive lesions was 14.5 for [ 18 To compare the tumor/background contrast between the two tracers, we calculated SUV values in suspicious lesions/ background in seven patients with maximum three lesions, detectable with both PET procedures. This resulted in a comparison of altogether 15 tumor/background ratios. Most of the suspected lymph node/bone metastases showed a higher SUV ratio for [ 18 F]DCFPyL using the kidney (Fig. 5a) or the spleen as a reference region, but no significant difference was found when using for the liver (Fig. 5b) or the mediastinum as reference organ. In detail, the mean tumor to background ratios between the SUV max in the PSMA-avid lesions with [ 18 F]DCFPyL and [ 68 Ga]Ga-PSMA-HBED-CC were 2.9 and 2.3 as compared with the SUV mean in the liver (p=0.167, n.s.), 4.3 and 2.1 as compared with the SUV mean in the spleen (p=0.002), 1.0 and 0.4 as compared with the SUV mean in the kidney (p= 0.006), 10.7 and 9.7 as compared with the SUV mean in the mediastinum (p=0.363, n.s.), and 1.4 and 0.9 as compared with the SUV mean in the parotid (p=0.008), respectively.
Clinical Consequences
In the majority of cases, [ 68 Ga]Ga-PSMA-HBED-CC and [ 18 F]DCFPyL PET/CT resulted in accumulating evidence, supporting further treatment decisions consistently. Both imaging series accordingly supported decisions towards core biopsy of the irradiated prostate in three patients, to local therapy options (lymph node dissection or radiotherapy) in four patients with one to two PSMA-positive lymph nodes and to systematic therapy in three patients. In four patients, neither imaging test detected a lesion explaining the rise in PSA levels. [ 18 F]DCFPyL PET/CT resulted in the detection of additional vertebral bone metastases in two patients (patient 2 and 12) in an oligometastatic state (patient 2 showed bone metastases also in [ 68 Ga]Ga-PSMA-HBED-CC PET/CT but to a lesser extent). This finding did not have immediate therapeutical consequences because both patients were asymptomatic at the time of their PET/CT examination. However, more accurate knowledge on the extent of bone metastases bears the potential to perform better targeted radiotherapy in the future (i.e., if the patients become symptomatic from their bone metastases). The detection of many PSMA-positive supradiaphragmatic lymph nodes with [ 18 F]DCFPyL in addition to retroperitoneal lymph node metastases also detected with [
68 Ga]Ga-PSMA-HBED-CC supported the decision to omit local radiotherapy of the retroperitoneal lymphatic pathways (patient 12). In one patient, a second PSMA-avid lymph node in the upper pelvis was detected with [ 18 F]DCFPyL in addition to another pelvic lymph node (detected with both tracers). In this patient, systematic bilateral pelvic lymph node dissection was performed and not influenced by the [ 18 F]DCFPyL findings. Unfortunately, only the larger metastasis (positive with both tracers) was detected intraoperatively and the patient remained PSA positive after surgery (patient 7).
Discussion
We analyzed 14 patients who underwent both [ 68 One explanation for the higher detection rate using [ 18 F]DCFPyL can be found in the higher injected dose, which allowed later acquisition times, potentially leading to better signal to noise ratios due to reduction of nonspecific signal. Lower background activity has been observed for the [ 18 F]DCFPyL in some organs such as the kidney. Independently from injected dose, faster clearance of the tracer from non-target tissue and higher affinity, may potentially have contributed to the detection of additional skeletal metastases observed for [ 18 68 Ge/ 68 Ga radionuclide generator but without own (cost-intense) cyclotron. However, a single preparation (0.3-0.6 GBq Ga-68) may only allow scanning up to two to four patients and the output depends on the half-life of the generator. As now established at our center, a single radiolabeling procedure of [ 18 F]DCFPyL resulted in a batch containing 6 to 7 GBq of [ 18 F]DCFPyL. This rendered it possible to examine six patients after a single preparation with an optimal dose, which represents an advantage for Another limitation can be found in the selection of patients. We did not recruit patients for both imaging series prospectively, and the selected population cannot serve as a representative sample. Due to the selection of patients with complex clinical questions (several of them being negative in [ 68 Ga]Ga-PSMA-HBED-CC PET/CT), it might be possible that the diagnostic accuracy of [ 68 Ga]Ga-PSMA-HBED-CC PET/CT is underestimated.
Comparison of the two tracers has not been carried out under identical conditions, i.e., mean injected dose and start of acquisition have been higher respectively later for [ 18 F]DCFPyL, as compared to [ 68 Ga]Ga-PSMA-HBED-CC PET/CT. It cannot be excluded that the performance of [ 68 Ga]Ga-PSMA-HBED-CC PET/CT would have been more similar to [ 18 F]DCFPyL under more identical examination conditions. However, it was the aim of this study to compare the two tracers under the circumstances usually available in clinical application. Generally, lower doses and earlier acquisition periods p.i. are selected for 68 Ga-labeled tracers. The time period of 1 h between injection of [ 68 Ga]Ga-PSMA-HBED-CC and the start of PET/CT was reported by many publications [2] [3] [4] [5] .
It was beyond the scope of an observational study to show time-activity curves. The time period of 2 h between the injection of [ 
